Posted by Michael Wonder on 26 Dec 2021
MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain
23 December 2021 - Piqray (alpelisib), in combination with fulvestrant, is approved for appropriate advanced breast cancer patients with a PIK3CA mutation after disease progression following endocrine-based therapy, providing eligible patients with more treatment options.
Today Novartis announced that the Medicines and Healthcare products Regulatory Agency has approved the marketing authorisation to extend the licence in Great Britain for Piqray (alpelisib) for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.
